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APROTININ AND 
METHYLPREDNISOLONE 
EQUALLY BLUNT 
CARDIOPULMONARY 
BYPASS-INDUCED 
INFLAMMATION IN 
HUMANS 
Cardiopulmonary bypass induces an inflammatory state characterized by 
tumor necrosis factor-oz release. Integrin CDl lb  is a neutrophil surface 
adhesive glycoprotein i tegrin that is rapidly and permanently unregulated 
by tumor necrosis factor.o~ exposure. The CDl lb  integrin is known to be the 
primary neutrophil integrin responsible for neutrophil lung and myocar- 
dial entrapment after cardiopulmonary b pass and subsequent reperfusion 
injury. Twenty-four adults admitted to the hospital for myocardial revas- 
cularization were equally randomized to one of three groups: group A 
(control), group B (methylprednisolone before cardiopulmonary b pass), 
and group C (low-dose aprotinin protocol). Blood was collected at three 
times: (1) baseline, (2) 50 minutes of cardiopulmonary b pass duration, 
and (3) 30 minutes after cardiopulmonary b pass termination. Neutrophil 
CDl lb integrin expression was measured by fluorescence-activated c ll
sorter analysis and plasma tumor necrosis factor-a levels measured by 
enzyme-linked immunosorbent assay. Group A demonstrated significant 
(p < 0.05) increases in CDl lb  expression at times 2 and 3 when results 
were compared with those of the same group baseline and with those of 
groups B and C at similar times. No significant changes were noted between 
groups B and C at any time. Group A demonstrated a significant (p < 0.05) 
increase in levels of tumor necrosis factor-oz at time 3 when results were 
compared with those of the same group baseline and of groups B and C at 
the same time. No significant changes were noted between groups B and C 
at any time. These results demonstrate low-dose aprotinin has a similar 
antiinflammatory effect to that of methylprednisolone i  blunting cardio- 
pulmonary bypass-induced systemic tumor necrosis factor-a release and 
neutrophil integrin CDl lb  upregulation. (J THORAC CARDIOVASC SURG 
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C ardiopulmonary bypass (CPB) induces a state 
characterized by systemic endotoxin and tumor 
necrosis factor (TNF) release. 1 Neutrophil integrin 
CDl lb  is rapidly 2and permanently 3 upregulated by 
cytokines, including TNF, 4 and is thought o be the 
primary neutrophil adhesive integrin responsible for 
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neutrophil organ entrapment, resulting in post-CPB 
reperfusion injury or lung 5' 6 and myocardium. 7 Al- 
though glucocorticoids are known to blunt TNF 
plasma levels 8 and neutrophil CD l lb  upregulation 9 
induced by CPB, the effect of aprotinin on these 
CPB-induced events has not previously been stud- 
ied. Previous studies have demonstrated aprotinin 
to reduce the cardiovascular response to endotoxin 
in an animal model 1° and to blunt interleukin-6 
release during CPB, 11 suggesting aprotinin may 
have a modifying effect on CPB-induced cytokine 
release and subsequent neutrophil CD l lb  upregu- 
lation. 
Methods 
After Institutional Review Board approval and patient 
informed consent were obtained, 24 male patients ched- 
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uled for elective aorta-coronary b pass were randomized 
equally to one of three groups: (1) a control group (group 
A), (2) a group that received methylprednisolone (1 gm 
intravenously) administered 5 minutes before CPB (group 
B), and (3) a group that received aprotinin, 140 mg 
intravenously asa loading dose, 140 mg in the pump prime 
and 35 mg. hr-1 as an intravenous constant infusion until 
chest closure (group C). 
On the morning of the operation, each patient was 
given morphine sulfate (0.1 mg/kg) and scopolamine (0.2 
to 0.4 rag) intramuscularly before admission to the oper- 
ating room. On arrival, a radial artery catheter, a right 
internal jugular vein pulmonary artery catheter, and large- 
bore intravenous lines were placed. Standard anesthetic 
treatment consisting of fentanyl (75 to 100 /xg/kg) as a 
short intravenous infusion and pancuronium (0.1 to 0.2 
mg/kg) was used. CPB was completed with a centrifugal 
pump (Medtronic Bio-Medicus, Inc., Eden Prairie, Minn.), 
hollow-fiber membrane oxygenator (Baxter Healthcare 
Corp., Irvine, Calif.) with arterial ine filtration, and mild 
hypothermia (32°C core temperature). Perfusion flow 
rate and mean arterial pressure during CPB were main- 
tained between 2.2 and 2.4 L.  rain -~ .m 2 ~ and 60 to 
80 mm Hg, respectively. Myocardial preservation was 
achieved through both antegrade and retrograde admin- 
istration of cold hyperkalemic blood (8 to 1 blood to 
crystalloid mixture) cardioplegic solution. A terminal dose 
of normothermic ontinuous cardioplegic solution was 
administered approximately 15 minutes before reperfu- 
sion. Anticoagulation i groups A and B was obtained by 
the administration of bovine lung heparin (300 IU/kg), 
and activated clotting times (ACTs) were maintained at 
greater than 480 seconds in all groups by the addition of 
heparin when necessary. Systemic anticoagulation in 
group C was achieved through the administration of 
bovine lung heparin (400 U/kg) to maintain kaolin-based 
ACTs greater than 600 seconds. At the termination of
CPB protamine was administered in a ratio of 1.3 mg for 
every 100 U of total heparin administration, and elficacy 
was confirmed by the return of the ACT to baseline 
values. 
Twenty milliliters of heparinized whole blood was 
drawn at three times: (1) baseline (after placement of the 
arterial and intravenous catheters but before anesthetic 
drug administration), (2) after 50 minutes of CPB, and (3) 
30 minutes after termination of CPB. No patient received 
blood products during periods 1 through 3. 
The blood samples were immediately taken to the 
laboratory. Laboratory personnel were blinded as to 
which group of the study each patient was assigned. 
Dextran (Pharmacia, Uppsala, Sweden) was added to the 
whole blood (1:2 dilution), and the sample was inverted 
several times and subjected to i g velocity sedimentation 
for 1 hour. The leukocyte-containing layer was removed 
and the neutrophils eparated by Ficoll-Hypaque (Sigma 
Chemical Co., St. Louis, Mo.) density centrifugation. 12 
After the sample was washed, integrin expression was 
detected with use of a double-antibody technique. Ten 
microliters of the first antibody, anti-CDllb antibody 
(Becton-Dickinson, San Jose, Calif.) or the isotype control 
was added and the sample incubated for 30 minutes. After 
the sample was washed, 10/zl of the second antibody, a 
Table L Age, weight, and duration of CPB for 
groups A, B, and C 
CPB 
Weight duration 
Age (yl 9 (kg) (rain) 
Group A 66 ± 3 76.3 + 3 73 2 3.1 
Group B 62 = 3.5 81.5 -+ 4 75.5 + 5 
Group C 61 _+ 4,5 80.5 _+ 3.6 79.4 + 5 
Values given as mean plus or minus the standard eviation. No significant 
differences were found between groups in any variable measured. 
fluorescein isothiocyanate conjugate of goat antimouse 
immunoglobulin (Becton-Dickinson), was added to the 
suspension and incubated for at least 30 minutes. The 
fluorescein-conjugated s cond antibody allows for a fluo- 
rescence-activated cell sorter (FACScan, Becton-Dickin- 
son) to quantify the surface xpression of each neutrophil 
surface integrin as described by Ledbetter and Herzen- 
berg.13 Flow cytometry data analysis (FACScan) was done 
with Lysis II software (Becton-Dickinson) and the data 
were expressed as mean fluorescence intensity on a linear 
scale, Mean fluorescence intensity was then used to 
evaluate differences between times and the three groups. 
TNF plasma levels were determined at the same time 
intervals used for neutrophil CDl lb integrin expression. 
Arterial blood for TNF-c~ levels was collected in sterile 20 
ml syringes, spun immediately at 2000 × g for 15 minutes, 
frozen at -80 ° C and batched. TNF-c~ was quantified by 
use of a "sandwich" enzyme-linked immunosorbent assay 
using specific monoclonaI antibodies (Quantikine HS, 
R & D Systems, Minneapolis, Minn.) after plasma thaw- 
ing and extraction were accomplished as described by 
others] 4 A repeated-measures analysis of variance was 
done to distinguish within-group differences over time, 
and t tests were done to evaluate differences at the same 
periods between groups; p values of 0.05 or less were 
considered significant. 
Results 
There were no significant differences between 
groups in age, weight, or CPB duration (Table I). 
CD l lb .  Group A demonstrated significant (p < 
0.05) increases in mean fluorescence intensity at 
times 2 and 3 when results were compared with 
those of the same group baseline. Groups B and C 
demonstrated no significant changes at a W time. 
When findings of group A were compared with 
those of groups B and C, a significant (p < 0.05) 
increase in mean fluorescence intensity was found to 
occur at times 2 and 3 (Fig. 1), 
TNF-m Group A demonstrated a significant in- 
crease (p < 0.05) in TNF-c~ plasma levels in period 
3 as compared with the level of  the same group 
baseline. Groups B and C demonstrated no signifi- 
cant changes at any time. When findings in group A 
were compared with those of groups B and C, a 
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Fig. 1. Mean fluorescence intensity of CD11b neutrophil 
integrin for groups A, B, and C at baseline, after 50- 
minute duration of CPB, and 30 minutes after CPB 
termination. SEM, Standard error of mean. *p < 0.05 
compared with baseline (group A) and compared with 
same times in groups B and C. 
significant (p < 0.05) increase in TNF plasma levels 
was found to occur at period 3 (Fig. 2). 
Discuss ion  
Originally used in the treatment of acute pancre- 
atitis, 15 aprotinin is now used primarily to reduce 
blood loss during cardiac operations. 16The hemo- 
static efficacy of aprotinin has been established with 
the most common dosing protocol of a 2 × 106 KIU 
(280 mg) loading dose with a 2 × 106 KIU (280 mg) 
pump prime dose and a continuous infusion of 
500,000 KIU/hr. 16' 17 Such high-dose protocols re- 
sulting in plasma levels of more than 250 KIU- m1-1 
have been shown to be no more effective in reducing 
post-CPB blood loss than low-dose (as used in this 
study) protocols resulting in plasma concentrations 
of 125 KIU.ml-1.1s'19 Reduced fibrin degration 
products, a;-plasmin inhibitor levels, ;° and im- 
proved platelet aggregation 21 have been reported 
with low-dose protocols during CPB in human be- 
ings, whereas high-dose aprotinin inhibits neutro- 
phil elastase release during simulated extracorpo- 
real perfusion, aa Aprotinin has been reported to 
inhibit interleukin-6 release during CPB 11 and im- 
proves neutrophil chemotaxis after aortic opera- 
tions a3 in human beings, and, in animal models, 
reduces extravascular water content in brain, heart, 
and lung after circulatory arrest. 24 Other animal 
studies demonstrate aprotinin blunts the circulatory 
consequences of endotoxin exposure. 1°' 25 Our data 
demonstrate aprotinin inhibits ystemic TNF release 
and subsequent neutrophil CDllb upregulation, 
"" 40-~ 
1,1,1 
t,/) 
+1 
E 30- 
1,1. 
Z 
I -  
,-, 20- 
E 
& 
> 
I1 
_1 
E 
eL 0 
F--~ Group A T 
I Group B ; .  
E~ Group C 
Baseline 50 min 30 min 
CPB After CPB 
Fig. 2. Plasma levels of TNF for groups A, B, and C at 
baseline, after 50-minute duration of CPB, and 30 minutes 
after CPB termination. SEM,, standard error of mean. *p 
< 0.05 compared with baseline (group A) and compared 
with same times in groups B and C. 
which is in further support of an antiinflammatory 
effect of aprotinin during CPB in human beings. 
Neutrophil surface adhesive protein (or integrin) 
CDllb and CDl la and CDllc make up the leuko- 
cyte integrins; each shares a common /3 subunit 
(CD18) but has distinct c~ subunits. 26 Activated 
neutrophils express primarily CDllb 26 and only 
CDllb has been shown to be upregulated during 
CPB.9, 27 Cytokines, including TNF, rapidly (2 to 4 
minutes);' 28 and permanently a9 upregulate CDllb 
expression. Neutrophil integrin CDllb is known to 
be the primary integrin involved in neutrophil ad- 
herence during reperfusion i jury in myocardium 3° 
and lung 6 after CPB. 
Glucocorticoids are known to blunt CPB-induced 
TNF release s but not CPB-induced endotoxemia. 31 
Glucocorticoids are also known to downregulate 
TNF production in human subjects after endotoxin 
infusions 3a and to inhibit the expression of the 
endothelial adhesion receptor (intercellular adhe- 
sion molecule 1) 33 to which neutrophil integrin 
CDllb adheres. 3'4 In addition, glucocorticoids are 
known to block CPB-induced neutrophil CD11b 
expression, presumably by blunting TNF release, 9 
and to reduce ndotoxin-stimulated alveolar macro- 
phage TNF release. 34 Although, few data exist that 
demonstrate an effect of aprotinin on cytokine gen- 
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eration or activity, TNF-induced cytotoxicity of rou- 
tine fibroblasts has been reported to be inhibited by 
aprotininY This study is the first report of the 
effects of aprotinin on reducing TNF release during 
CPB in human beings. 
In summary, low-dose aprotinin administered be- 
fore and during CPB in human beings reduces 
systemic TNF release and subsequent neutrophil 
CD l lb  upregulation. This effect of aprotinin is 
similar to that found in a comparable group of 
patients given a glucocorticoid (methylpredniso- 
lone) only. These data demonstrate aprotinin to 
have an antiinflammatory effect during CPB in 
human beings. 
Statistical analysis was done, in part, by Elizabeth Ruby, 
MS, Department of Preventive and Societal Medicine, 
University of Nebraska Medical Center. 
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